Results 181 to 190 of about 2,405,285 (205)
Some of the next articles are maybe not open access.

[Assessing the added benefit of new ophthalmic drugs : Which additional insights can be extracted from the early benefit assessment?]

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2019
Until now six ophthalmic agents have undergone the German early benefit assessment according to § 35a Social Security Code (SGB) V in a total of eleven indications. Only one agent (ocriplasmin) was recognized by the Federal Joint Committee as having an added benefit based on submitted study data for a subpopulation (indication of a considerable added ...
M, Appelrath, G, Glaeske
openaire   +1 more source

[Subgroups in the early benefit assessment of pharmaceuticals: a methodical review].

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen, 2016
Benefit assessments according to Sect. 35a of the Social Code Book V are frequently divided into subsets of populations. This division of therapeutic indications is evident in almost every other of the completed appraisals by the Federal Joint Committee (G-BA).
Andrej, Rasch   +1 more
openaire   +1 more source

HTA122 Health-Related Quality of Life in the German Early Benefit Assessment

Value in Health, 2022
M Barth   +4 more
openaire   +1 more source

Local Surgical, Ablative, and Radiation Treatment of Metastases

Ca-A Cancer Journal for Clinicians, 2009
Yuman Fong   +2 more
exaly  

American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer

Ca-A Cancer Journal for Clinicians, 2002
Carolyn D Runowicz, Robert A Smith
exaly  

Home - About - Disclaimer - Privacy